| Tallassee Health And Rehabilitation, Llc | |
| 2639 Gilmer Avenue, Tallassee, Alabama 36078 | |
| (334) 283-3975 | |
| Name | Tallassee Health And Rehabilitation, Llc |
|---|---|
| Location | 2639 Gilmer Avenue, Tallassee, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 111 |
| Occupancy Rate | 66.04% |
| Medicare ID (CCN) | 015139 |
| Legal Business Name | Tallassee Health And Rehabilitation, Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1992752745 |
| Organization Name | TALLASSEE HEALTH AND REHABILITATION, LLC |
| Address | 2639 Gilmer Ave, Tallassee, AL 36078 |
| Phone Number | 334-283-3975 |
News Archive
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
Researchers at Oregon State University have found one gene in the human body that appears to be a master regulator for skin development, in research that could help address everything from skin diseases such as eczema or psoriasis to the wrinkling of skin as people age.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
Researchers at Oregon State University have found one gene in the human body that appears to be a master regulator for skin development, in research that could help address everything from skin diseases such as eczema or psoriasis to the wrinkling of skin as people age.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.13 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.28 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 43.3 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 3.79 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.23 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 26.06 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.88 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 32.96 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.69 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 11.56 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 32.98 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 98.07 | 82.93 |
News Archive
Itamar-Medical, the world's leader of non-invasive devices for diagnosis of cardiovascular health, announced achievement of the next milestone of the international pharmaceutical company, Roche, to further develop the EndoPAT technology for pre-clinical trials.
Nanomix Inc., a leading nanotechnology company focused on development of next generation point of care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings, announced today that the United States Patent and Trademark Office has allowed a patent application relating to flexible nanostructure electronic devices, such as nanotube sensors and transistors, and method for fabricating the same.
Researchers at Oregon State University have found one gene in the human body that appears to be a master regulator for skin development, in research that could help address everything from skin diseases such as eczema or psoriasis to the wrinkling of skin as people age.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).
› Verified 9 days ago
Tallassee Health And Rehabilitation, Llc Location: 2639 Gilmer Avenue, Tallassee, Alabama 36078 Phone: (334) 283-3975 |